Sica DANewer antihypertensive agents: Angiotensin-receptor antagonists and aldosterone receptor antagonists. In: Atlas of Hypertension . Hollenberg N (Ed) (5th edition). Current Medicine, Inc. Philadelphia, PA. 2005:326-50.
2.
Sica DA, Gehr TW, Ghosh S.Clinical pharmacokinetics of losartan. Clin Pharmacokinet2005;44:797-814.
3.
Gleiter CH, Morike KEClinical pharmacokinetics of candesartan. Clin Pharmacokinet2002;41:7-17.
4.
Mire DE, Silfani TN, Pugsley MKA review of the structural and functional features of olmesartan medoxomil, an angiotensin receptor blocker. J Cardiovasc Pharmacol2005;46:585-93.
Sica DAAngiotensin receptor blockers - new considerations in their mechanism of action . J Clinical Hypertension2006;8;381-5.
7.
Maillard MP , Wurzner G., Nussberger J. et al. Comparative angiotensin II receptor blockade in healthy volunteers: the importance of dosing. Clin Pharmacol Ther2002;71:68-76.
8.
White WB, Lacourciere Y., Davidai G.Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period. Am J Hypertens2004; 17:347-53.
9.
Weisser B., Gerwe M., Braun M., Funken C.[Investigations of the antihypertensive long-term action of candesartan cilexetil in different dosages under the influence of therapy-free intervals]Arzneimittelforschung2005;55:505-13.
10.
Sica DA, Gehr TWB, Frishman WHThe renin-angiotensin axis: Angiotensin converting enzyme inhibitors and angiotensin-receptor blockers. In: Frishman W, Sonnenblick S, Sica DA (eds.) Cardiovascular Pharmacotherapeutics (2nd edition). New York, NY : McGraw-Hill. 2003: pp. 131-56.
11.
Leblanc JM, Dasta JF, Pruchnicki MC, Schentag JJImpact of disease states on the pharmacokinetics and pharmacodynamics of angiotensin-converting enzyme inhibitors. J Clin Pharmacol2006;46:968-80.
12.
Dzau VJ, Bernstein K., Celermajer D. et al. The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint data. Am J Cardiol2001;88 (suppl 9):1L-20L.
13.
Rahuel J., Rasetti V., Maibaum J. et al. Structure-based drug design: the discovery of novel non peptide orally active inhibitors of human renin. Chem Biol2000;7:493-504.
14.
Nussberger J., Wuerzner G., Jensen C., Brunner HRAngiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP100): comparison with enalapril . Hypertension2003 ;39:E1-E8.
15.
Azizi M., Webb R., Nussberger J., Hollenberg NKRenin inhibition with aliskiren: where are we now and where are we going?J Hypertens2006;24:243-56.
16.
Zhao C., Vaidyanathan S., Yeh CM et al. Aliskiren exhibits similar pharmacokinetics in healthy volunteers and patients with type 2 diabetes mellitus. Clin Pharmacokinet2006;45:1125-34.
17.
Vaidyanathan S., Limoges D., Yeh C., Dieterich H.Aliskiren, an orally effective renin inhibitor, shows dose linear pharmacokinetics in healthy volunteers. Clin Pharmacol Ther2006 ;79:64(PIII-23).
18.
Vaidyanathan S., Jin Y., Schiller H., Jensen C.Aliskiren, a novel oral renin inhibitor, has no interaction with cytochrome P450 isoenzymes in vitro. Bas Clin Pharmacol Toxicol;97(suppl 1).
19.
Gradman AH, Schmieder RE, Lins RL et al. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients . Circulation2005;111: 1012-18.
20.
Sica D., Gradman A., Lederballe I. et al. Aliskiren, an oral renin inhibitor, provides long-term antihypertensive efficacy and safety in patients with hypertension. Eur Heart J2006;27(suppl):P797.
21.
Feldman DL, Persohn E., Schutz H. et al. Renal localization of the renin inhibitor aliskiren. J Clin Hypertens2006;8 (suppl A):A80.
22.
Herron J., Mitchell J., Oh B. et al. The novel renin inhibitor aliskiren is not associated with rebound effects on blood pressure or plasma renin activity following treatment withdrawal . J Clin Hypertens2006;8(suppl A):A86.
